D.E. Shaw & Co
PTGX icon

D.E. Shaw & Co’s Protagonist Therapeutics PTGX Stock Holding History

D.E. Shaw & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,361
Closed -$2.29M – 4650
2025
Q1 		$2.29M Buy
47,361
+41,657
+730% +$1.75M ﹤0.01% 2504
2024
Q4 		$220K Sell
5,704
-21,121
-79% -$921K ﹤0.01% 4046
2024
Q3 		$1.21M Buy
26,825
+13,673
+104% +$552K ﹤0.01% 3127
2024
Q2 		$456K Sell
13,152
-22,488
-63% -$659K ﹤0.01% 3681
2024
Q1 		$1.03M Buy
+35,640
New +$970K ﹤0.01% 3074
2023
Q3 		– Sell
-72,686
Closed -$2.01M – 4438
2023
Q2 		$2.01M Sell
72,686
-126,830
-64% -$3.17M ﹤0.01% 2619
2023
Q1 		$4.59M Buy
199,516
+11,480
+6% +$193K ﹤0.01% 2005
2022
Q4 		$2.05M Buy
188,036
+44,961
+31% +$379K ﹤0.01% 2926
2022
Q3 		$1.21M Buy
+143,075
New +$1.35M ﹤0.01% 3451
2022
Q1 		– Sell
-43,286
Closed -$1.48M – 5854
2021
Q4 		$1.48M Sell
43,286
-72,627
-63% -$2.3M ﹤0.01% 3616
2021
Q3 		$2.05M Sell
115,913
-132,322
-53% -$5.64M ﹤0.01% 3016
2021
Q2 		$11.1M Buy
248,235
+47,255
+24% +$1.56M 0.01% 1406
2021
Q1 		$5.21M Sell
200,980
-135,876
-40% -$3.44M 0.01% 1812
2020
Q4 		$6.79M Sell
336,856
-190,977
-36% -$4.11M 0.01% 1641
2020
Q3 		$10.3M Sell
527,833
-285,113
-35% -$5.35M 0.01% 1225
2020
Q2 		$14.4M Buy
812,946
+532,412
+190% +$6.68M 0.02% 972
2020
Q1 		$1.98M Sell
280,534
-149,983
-35% -$1.12M ﹤0.01% 2179
2019
Q4 		$3.04M Buy
430,517
+100,348
+30% +$997K ﹤0.01% 2141
2019
Q3 		$3.97M Sell
330,169
-67,109
-17% -$846K ﹤0.01% 1827
2019
Q2 		$4.81M Buy
397,278
+139,550
+54% +$1.54M 0.01% 1616
2019
Q1 		$3.24M Buy
257,728
+238,083
+1,212% +$2.1M ﹤0.01% 1828
2018
Q4 		$132K Buy
19,645
+8,450
+75% +$67K ﹤0.01% 3612
2018
Q3 		$115K Sell
11,195
-39,066
-78% -$336K ﹤0.01% 3612
2018
Q2 		$337K Buy
+50,261
New +$386K ﹤0.01% 3319
2018
Q1 		– Sell
-31,251
Closed -$650K – 3736
2017
Q4 		$650K Buy
+31,251
New +$554K ﹤0.01% 2827

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's PTGX Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 47,361 shares — an estimated $2.29M sold.

D.E. Shaw & Co first reported a position in PTGX in Q4 2017 and held it in 25 quarters. The position peaked at $14.4M in Q2 2020. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 47,361 Protagonist Therapeutics shares in Q2 2025, an estimated $2.29M.
  • D.E. Shaw & Co first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 25 quarters.
  • D.E. Shaw & Co's Protagonist Therapeutics position peaked at $14.4M in Q2 2020.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.